Samidorphan mitigates olanzapine-induced weight gain and metabolic dysfunction in rats and non-human primates

Volume: 33, Issue: 10, Pages: 1303 - 1316
Published: Jul 11, 2019
Abstract
Background: Olanzapine, regarded as one of the most efficacious antipsychotic medications for the treatment of schizophrenia, is associated with a high risk of weight gain and metabolic dysfunction. ALKS 3831, a clinical candidate for treatment of schizophrenia, is a combination of olanzapine and samidorphan, an opioid receptor antagonist. The addition of samidorphan is intended to mitigate weight gain and the metabolic dysregulation associated...
Paper Details
Title
Samidorphan mitigates olanzapine-induced weight gain and metabolic dysfunction in rats and non-human primates
Published Date
Jul 11, 2019
Volume
33
Issue
10
Pages
1303 - 1316
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.